Review Article

Genetics and Epigenetics of Parkinson’s Disease

Fabio Coppede\textsuperscript{1,2}

\textsuperscript{1}Faculty of Medicine, University of Pisa, 56126 Pisa, Italy
\textsuperscript{2}Genetics and Epigenetics of Complex Disease Program, Department of Neuroscience (DAI Neuroscience), Pisa University Hospital, Via S. Giuseppe 22, 56126 Pisa, Italy

Correspondence should be addressed to Fabio Coppede, f.coppede@geog.unipi.it

Received 15 October 2011; Accepted 21 December 2011

Academic Editors: H. Cui and M. Hiltunen

Copyright © 2012 Fabio Coppede. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In 1997 a mutation in the \textit{a-synuclein} (SNCA) gene was associated with familial autosomal dominant Parkinson’s disease (PD). Since then, several loci (PARK1-15) and genes have been linked to familial forms of the disease. There is now sufficient evidence that six of the so far identified genes at PARK loci (\textit{a-synuclein}, leucine-rich repeat kinase 2, parkin, PTEN-induced putative kinase 1, DJ-1, and ATP13A2) cause inherited forms of typical PD or parkinsonian syndromes. Other genes at non-PARK loci (MAPT, SCA1, SCA2, spastacin, POLG1) cause syndromes with parkinsonism as one of the symptoms. The majority of PD cases are however sporadic “idiopathic” forms, and the recent application of genome-wide screening revealed almost 20 genes that might contribute to disease risk. In addition, increasing evidence suggests that epigenetic mechanisms, such as DNA methylation, histone modifications, and small RNA-mediated mechanisms, could regulate the expression of PD-related genes.

1. Genetics of Parkinson’s Disease (PD)

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1-2% of the population over the age of 65 years and reaching a prevalence of almost 4% in those aged above 85 years. Resting tremor, rigidity, bradykinesia, and postural instability are the main clinical symptoms of the disease often accompanied by nonmotor symptoms including autonomic insufficiency, cognitive impairment, and sleep disorders. The brain of PD individuals is pathologically characterized by a progressive and profound loss of neuromelanin containing dopaminergic neurons in the \textit{substantia nigra} with the presence of eosinophilic, intracytoplasmic inclusions termed as Lewy bodies (LBs: containing aggregates of \textit{a-synuclein} as well as other substances), and Lewy neurites in surviving neurons. Unfortunately, only some improvements of the symptoms are offered by current treatments based on levodopa and dopaminergic therapy, but there is no currently available treatment to arrest the progression of the disease [1].

A familial history of PD is shown in approximately 20% of the cases, and in a minority of them the disease follows Mendelian inheritance patterns. Studies in PD families led to the identification of 15 PD loci (PARK1-15), and 11 genes for PARK loci have so far been described (Table 1). Although follow-up genetic studies have been inconsistent for some of them or conclusive data are still pending, there is evidence that five of those genes (\textit{a-synuclein}, parkin, PTEN-induced putative kinase 1, DJ-1, and leucine-rich repeat kinase 2) cause typical PD [2], and mutations of ATP13A2 (PARK9) cause Kufor-Rakeb disease, an autosomal recessive parkinsonism with many other features, including pyramidal tract dysfunction, supranuclear gaze paresis, and dementia [3]. The vast majority of PD cases are however sporadic (idiopathic) forms, likely resulting from a combination of polygenic inheritance, environmental exposures, and complex gene-environment interactions superimposed on slow and sustained neuronal dysfunction due to aging [4]. Therefore, linkage analyses in PD families have been paralleled by several hundreds of genetic association studies in order to identify genetic variants able to modify the individual risk to develop idiopathic forms of the disease. These studies have been conducted by either the candidate gene approach or, more recently, by means of genome-wide screenings, that is, genome-wide association studies (GWASs). The genetic screening has been successful with a common high-risk locus
identified (GBA), and many common low-risk loci (SNCA, MAPT, LRRK2) were recently elucidated [24]. Moreover, the application of GWAS technology and the creation of international collaborative groups sharing samples and results are continuously revealing novel variants that could contribute to disease risk [25].

The last few years have seen the growing of evidence dealing with the possible contribution of epigenetic modifications to human diseases, including among others neurodegenerative ones [26–28]. The term “epigenetics” is used to describe those mechanisms able to modify the expression levels of selected genes without necessarily altering their DNA sequence, including DNA methylation, histone tail modifications, and chromatin remodeling, as well as mechanisms mediated by small RNA molecules. Epigenetic modifications, and chromatin remodeling, as well as mechanisms mediated by small RNA molecules. Epigenetic modifications likely contributing to PD pathogenesis.

2. Familial Parkinson’s Disease

There is sufficient evidence that six of the so far identified genes at PARK loci cause inherited forms of typical PD or parkinsonian syndromes. Only two of them (α-synuclein and leucine-rich repeat kinase 2) cause autosomal dominant forms, whilst the other four (parkin, PTEN-induced putative kinase 1, DJ-1, and ATP13A2) are inherited in an autosomal recessive fashion. Additional PARK loci have been so far described (Table 1), pending identification of a causative gene or confirmation/validation of the candidate one. Moreover, in addition to the genes mapped to the sequentially numbered PARK1-15 loci, other genes, such as MAPT, ATXN2, ATXN3, spatacin, and POLG1 (Table 2), are known to cause syndromes that can clinically manifest with parkinsonism as one of the symptoms [24].

### 2.1. Autosomal Dominant PD

#### 2.1.1. α-Synuclein (SNCA): PARK1 and PARK4

In 1997 Polymeropoulos et al. [5] described a mutation in the α-synuclein gene (SNCA) on 4q21 (PARK1), causing an A53T amino acid substitution and segregating with PD in an Italian kindred and 3 unrelated families of Greek origin [5]. Two additional SNCA mutations (A30P and E46K) were subsequently described in other families with autosomal dominant PD [6, 7]. Moreover, a triplication of the α-synuclein gene (PARK4) was observed in a large family as causative of PD [8], and other PD families have been described with α-synuclein gene duplication and a disease course less severe of that observed in PARK4 carriers, suggesting the existence of a gene dosage effect [9]. Although SNCA has been the first PD gene identified, SNCA mutations and multiplications are both extremely rare causes of familial autosomal dominant PD [2]. α-Synuclein is expressed throughout the mammalian brain particularly in presynaptic nerve terminals, and mutated α-synuclein has an increased tendency to form aggregates critical to Lewy bodies (LBs) formation. These fibrillar aggregates are the major component of LBs in both familial and idiopathic PD, and aggregation of α-synuclein is thought to be a key event in dopaminergic neuronal cell death. The function of α-synuclein under normal physiological conditions is not yet completely clear, although there is evidence that implicates SNCA in neurotransmitter release and vesicle turnover at the presynaptic terminals [39, 40].

#### 2.1.2. Leucine-Rich Repeat Kinase 2 (LRRK2): PARK8

The LRRK2 gene was mapped on the PARK8 locus in 12q12 and was the second gene linked to autosomal dominant PD [10, 11]. Over 100 LRRK2 mutations have been so far described in PD families and sporadic cases, but the pathogenic role of many of them has not yet been proven (a complete list can be

---

### Table 1: Loci and genes associated with familial PD.

| Designation | Locus | Gene | Inheritance* | Refs |
|-------------|-------|------|--------------|------|
| Validated loci |       |      |              |      |
| PARK1/PARK4 | 4q21  | SNCA | AD           | [5–16] |
| PARK8      | 12q12 | LRRK2| AD           |       |
| PARK2      | 6q25.2-27 | PARK | AR           |       |
| PARK6      | 1p35-36 | PINK1| AR           |       |
| PARK7      | 1p36  | DJ-1 | AR           |       |
| PARK9      | 1p36  | ATP13A2 | AR  |       |
| Other loci |       |      |              |      |
| PARK3      | 2p13  | Unknown | AD | [17–23] |
| PARK5      | 4p14  | UCH-L1| AD           |       |
| PARK8      | 12q12 | LRRK2| AD           |       |
| PARK10     | 1p32  | Unknown | Not clear  |       |
| PARK11     | 2q36-37 | GIGYF2| AD           |       |
| PARK12     | Xq21-q25 | Unknown | X-linked |       |
| PARK13     | 2p12  | OMН/HTRA2| AD |       |
| PARK14     | 22q13.1 | PLA2G6 | AR |       |
| PARK15     | 22q11.2-pter | FBXO7 | AR |       |

*AD: autosomal dominant; AR: autosomal recessive.

### Table 2: Additional genes causing parkinsonism.

| Gene  | Disease                                      | Refs |
|-------|----------------------------------------------|------|
| MAPT  | Frontotemporal dementia with parkinsonism linked to chromosome 17 | [30–38] |
| ATXN2 | Spinocerebellar ataxia type 2 and parkinsonism |       |
| ATXN3 | Spinocerebellar ataxia type 3 and parkinsonism |       |
| SPG11 | Hereditary spastic paraplegia and parkinsonism |       |
| POLG1 | Mitochondrial parkinsonism                   |       |
found at: http://www.molgen.ua.ac.be/PDmutDB/). LRRK2 encodes a protein named dardarin (from dardara, the Basque word for tremor) which contains several domains including the catalytic domain of a tyrosine kinase. The presence of a kinase domain suggests a role for dardarin in signaling cascades, likely relating to cytoskeletal dynamics [24]. The most prevalent LRRK2 mutation is a G2019S missense mutation occurring in 1-2% of PD patients of European origin, 20% of Ashkenazi Jewish patients, and approximately 40% of Arab Berbers with PD. The Arg1441 codon is another frequent hotspot of LRRK2 pathogenic mutations [2].

2.2. Autosomal Recessive PD

2.2.1. Parkin: PARK2. Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations of the parkin gene on chromosome 6q25.2–q27 (PARK2) [12]. The disease is characterized by early onset and a marked response to levodopa treatment and differs from idiopathic PD in that there is usually no LBs formation. Over 100 mutations in parkin, including missense mutations and exonic deletions and insertions, have been observed in PD families [41]. Parkin is a ubiquitin E3 ligase preparing target proteins for their degradation mediated by the ubiquitin-proteosomal system [42]. Moreover, parkin is involved in mitochondrial maintenance, repair of mitochondrial DNA damage, might contribute to mitochondrial respiratory chain dysfunction, and induce subsequent autophagy of dysfunctional mitochondria [43–47].

2.2.2. PTEN-Induced Putative Kinase 1 Gene (PINK-1): PARK6. Mutations in the PTEN-induced putative kinase 1 (PINK-1) gene on chromosome 1p35-36 (PARK6) have been linked to autosomal recessive early-onset PD [13]. Several different PINK1 mutations, primarily missense and nonsense ones, have been identified in PD families worldwide and cause mitochondrial deficits contributing to PD pathogenesis (http://www.molgen.ua.ac.be/PDmutDB/). PINK1 is a kinase with an N-terminal mitochondrial targeting sequence, provides protection against mitochondrial dysfunction, and regulates mitochondrial morphology via fission/fusion machinery. PINK1 also acts upstream of parkin in a common pathway in the maintenance of mitochondrial quality via autophagy [48].

2.2.3. DJ-1: PARK7. Mutations in the DJ-1 gene on 1p36 (PARK7), including exonic deletions and point mutations, have been associated with a monogenic early-onset autosomal recessive form of parkinsonism characterized by slow progression and response to levodopa [14, 15]. A complete list of DJ-1 mutations can be found at the PD mutation database (http://www.molgen.ua.ac.be/PDmutDB/). DJ-1 is a mitochondrial protein involved in the protection against oxidative stress and forms a complex with parkin and PINK1 to promote ubiquitination and degradation of parkin substrates, including parkin itself [49]. Recent evidence indicates that DJ-1 works in parallel to the PINK1/parkin pathway to maintain mitochondrial function in the presence of an oxidative environment [50].

2.2.4. ATP13A2 Gene: PARK9. Clinical features similar to those of idiopathic PD and polyynodyskinesia syndrome, including parkinsonism, pyramidal tract dysfunction, supranuclear gaze paresis, and dementia, were observed in a Jordanian family. The pattern of transmission was autosomal recessive, and a region of linkage was identified on chromosome 1p36 (PARK9) [16]. The causative gene underlying PARK9 was then identified as the ATP13A2 gene encoding a lysosomal 5 P-type ATPase [3] likely involved in the regulation of intracellular manganese homeostasis [51].

2.3. Additional PARK Loci. Additional putative PARK loci include: (1) a locus on 2p13, denoted as PARK3 but with no causative gene yet identified; (2) the UCH-L1 gene on 4p14 (PARK5) coding for a protein that possesses both a hydrolase activity to generate the ubiquitin monomer and a ligase activity to link ubiquitin molecules to tag proteins for disposal; (3) a locus on 1p32, denoted as PARK10 but with no causative gene yet identified; (4) the GYGF2 gene on 2q36-37 (PARK11), encoding a protein that could participate in the regulation of signaling at endosomes; (5) a locus on 4q21-q25, denoted as PARK12 and showing X-linked inheritance, but still pending characterization of the causative gene; (6) the OMI/HTRA2 gene on chromosome 2p12 (PARK13) encoding for a nuclear-encoded serine protease localized in the intermembrane space of the mitochondria and involved in mediating caspase-dependent and caspase-independent cellular death; (7) the PLA2G6 gene on chromosome 22q13.1 (PARK14) encoding a calcium-independent group VI phospholipase A2; (8) the FBXO7 gene on 22q11.2-qter (PARK15) encoding for a member of the F-box family of proteins, all of which may have a role in the ubiquitin-proteasome protein-degradation pathway [17–23].

2.4. Other Loci. Parkinsonism is often observed as one of the symptoms in other monogenic diseases (Table 2). For example, the MAPT gene encodes for the microtubule-associated protein tau, a protein that binds to microtubules and is primarily involved in the organization and integrity of the cytoskeleton. Hyperphosphorylated tau forms neurofibrillary tangles in Alzheimer’s disease brains, and mutations of MAPT cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [30, 31]. Parkinsonism, dystonia, and postural tremor are particularly prevalent in spinocerebellar ataxias types 2 (SCA2) and 3 (SCA3). SCA2 can manifest either with a cerebellar syndrome or as Parkinson's syndrome, and SCA3, also known as Machado-Joseph disease (MJD), is the most common form of spinocerebellar ataxia worldwide. The diseases are caused by abnormal CAG trinucleotide repeat expansion of ataxin-2 (ATXN2) and ataxin-3 (ATXN3) genes, respectively [32, 33]. Ataxin-2 is an enzyme involved in RNA processing, whilst ataxin-3 is a deubiquitinating enzyme involved in the ubiquitin-proteasome system. The parkinsonian phenotype of both diseases is often observed in Asians [34, 35]. Autosomal recessive hereditary spastic paraplegia with thin corpus callosum (SPG11) is a rare neurodegenerative disorder often caused by mutations in the gene encoding for spatacsin at the SPG11 locus on
chromosome 15q. Two patients, of Turkish descent, from the same consanguineous family, were affected with SPG11 in association with unusual early-onset parkinsonism that occurred during the very early stages of SPG11 in both patients [36]. Additional evidence indicates that mutation of SPG11 is a rare cause of early-onset levodopa-responsive parkinsonism with pyramidal signs [37]. There is also indication that rearrangements of the gene coding for the mitochondrial DNA polymerase gamma (POLG1), involved in the repair of mitochondrial DNA, can directly cause parkinsonism [38].

3. Sporadic Parkinson’s Disease

Several hundreds of genetic association studies have been performed in the last few decades by means of the candidate gene approach in order to identify genetic risk factors for non-Mendelian forms of PD.

The candidate gene was selected based on the knowledge of its function in a pathway related to PD pathogenesis, and only one single gene and one or a few polymorphisms were usually investigated. More recently, those studies have been replaced by GWAS where half a million or more polymorphisms are simultaneously investigated in large case-control cohorts. GWASs are currently considered as the gold standard to find loci at which common, normal genetic variations contribute to disease risk, and their introduction has revolutionized our knowledge in the genetics of sporadic PD [24]. The PDGene database [52] is a public and continuously updated database collecting data from PD genetic association studies and GWAS. Accessed on October 2011, the database contained information on 860 studies for a total of 909 candidate genes and 3434 polymorphisms within those genes. In addition, data from GWAS and other large-scale studies were available [52]. There is strong consensus from either GWAS or updated meta-analyses of the literature that variants at four loci (SNCA, MAPT, GBA and LRRK2) contribute to disease risk (Table 3). In addition, recent GWASs have revealed novel putative PD risk loci to be confirmed in future studies [25], and the meta-analysis of the literature suggests that several additional loci could contribute to disease risk [52] (Table 3).

3.1. α-Synuclein (SNCA). Common polymorphisms of causative PD genes have been frequently investigated as possible risk factors for the idiopathic forms of the disease. Particularly, genetic polymorphisms in the SNCA gene have been consistently associated with PD risk in genetic association studies and subsequently replicated in large-scale GWAS, including a dinucleotide repeat sequence (Rep1) within the promoter region and several single nucleotide polymorphisms (SNPs) at the 3’end of the gene, overall suggesting that SNCA alleles associated with increased disease risk correlate with higher α-synuclein expression, and pointing to a gene dosage effect [52–60]. Meta-analyses of those studies revealed that SNCA is a low-risk locus for idiopathic PD, with odds ratios (ORs) ranging from 1.2 to 1.4 [52].

3.2. Leucine-Rich Repeat Kinase 2. Variants of LRRK2 have been consistently associated with increased risk for sporadic PD in Asians, including a G2385R polymorphism [61] that represents one of the most frequent genetic risk factors for PD in Asian populations, with an estimated OR of 2.2 [52].

3.3. Microtubule-Associated Protein Tau: MAPT. As described earlier in this paper, mutations of MAPT cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). Moreover, large case-control studies, meta-analyses of the literature, and GWAS indicate a role for the MAPT haplotype H1 to disease risk [52, 62, 63].

3.4. Glucocerebrosidase: GBA. Gaucher disease (GD) is an autosomal recessive lysosomal glycolipid storage disorder caused by mutations of the GBA gene encoding the enzyme glucocerebrosidase. A small subset of GD patients develop parkinsonism [64] and relatives of patients with GD have an increased incidence of parkinsonism [65]. Large cohort studies [66] and recent meta-analyses of the literature revealed that GBA loss of function variants are the most common genetic risk factor associated with parkinsonism, with an estimated OR of 3.4 for the common GBA N370S variant [52]. Although the mechanism for this association is unknown, several theories have been proposed, including protein aggregation, lipid accumulation, and impaired autophagy, mitophagy, or trafficking [67].

3.5. Additional Loci. The application of GWAS to the understanding of the genetics of sporadic PD has significantly

| Gene or locus | Methodologies employed | Refs |
|--------------|------------------------|------|
| SNCA         | Large-scale association studies | [25, 52–68] |
| LRRK2        |                         |      |
| MAPT         | Meta-analyses of genetic association studies | |
| GBA          | GWAS                  |      |
| HLA-DRB5     | Meta-analyses of GWAS  |      |
| BST1         | GWAS                  |      |
| GAK          | Meta-analyses of GWAS  |      |
| ACM0D        | GWAS                  |      |
| STK39        | GWAS                  |      |
| MCCC1/LAMP3  | GWAS                  |      |
| SYT11        | GWAS                  |      |
| CCDC62/HIP1R | GWAS                  |      |
| PARK16/1q32  | GWAS                  |      |
| STX1B        | GWAS                  |      |
| GWA 8p22     | GWAS                  |      |
| STBD1        | GWAS                  |      |
| GPNMB        | GWAS                  |      |
| PM20D1       | GWAS                  |      |
| SETD1A       | GWAS                  |      |
| FAM47E       | GWAS                  |      |
| MED13        | GWAS                  |      |

Table 3: Genes or loci associated with idiopathic PD.
improved our knowledge in the field, and several loci have been associated with disease risk in recent years. A recent meta-analysis of published GWAS was performed by the International Parkinson Disease Genomics Consortium (IPDGC) for a total of 12,386 PD cases and 21,026 controls and suggested that, in addition to SNCA, LRRK2, and MAPT polymorphisms, variants at eight additional loci (HLA-DRB5, BST1, GAK, ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R) are significantly associated with disease risk [25]. A more recent two-stage meta-analysis performed by the IPDGC and the Wellcome Trust Case Control Consortium 2 (WTCCC2) revealed five additional loci associated with PD risk (PARK16/1q32, STX1B, GWA 8p22, STBD1, GPNMB) [68]. Up to date meta-analyses are available also at the PDGene database for each polymorphism that has been evaluated in at least four independent genetic association studies. Accessed on October 2011 the PDGene database contained 886 updated meta-analyses of the literature, overall suggesting that 18 loci could contribute to sporadic PD risk, including most of those already described (SNCA, LRRK2, MAPT, GBA, HLA-DRB5, BST1, GAK, ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R, GWA 8p22, GPNMB) and additional ones (PM20D1, SETD1A, FAM47E and MED13) [52].

4. Epigenetics of Parkinson’s Disease

4.1. DNA Methylation. DNA methylation represents one of the most important epigenetic processes, along with histone modifications and mechanisms involving small RNA molecules. Methylation of CpG sequences might induce chromatin conformational modifications and inhibit the access of the transcriptional machinery to gene promoter regions, thus altering gene expression levels. Therefore, promoter hypermethylation is commonly associated with gene silencing and promoter demethylation with gene expression, even if some exceptions to this rule are known [69]. Folate, other B vitamins (vitamins B6 and B12), and homocysteine (hcy) participate in one-carbon metabolism, a complex pathway required for the production of S-adenosylmethionine (SAM), the major intracellular methylating agent. DNA methylation is closely dependent on the DNA potential, which is referred to as the ratio between SAM and S-adenosylhomocysteine (SAH) levels. DNA methyltransferases (DNMTs) are the key enzymes for DNA methylation and catalyze the transfer of a methyl group from SAM to cytosine, thus forming 5-methyl-cytosine. Impaired one-carbon metabolism, altered DNA methylation potential, reduced DNA methylation levels in the brain, and altered methylation and expression of several genes were observed in Alzheimer’s disease (AD) patients, pointing to a role for epigenetic modifications in the neurodegenerative process [26]. Less studies have been so far performed in PD subjects; however, there is indication of impaired one-carbon metabolism in PD as well as altered DNA methylation potential [70, 71]. Epigenetic analyses of PD brains revealed that the SNCA gene could be subjected to epigenetic regulation [72, 73]. In addition, more recent large-scale studies suggest that other PD-related genes could be epigenetically modified in PD brains (Table 4) [68].

4.1.1. α-Synuclein. Several lines of evidence, including the identification of families with SNCA locus duplication and triplication and the association of both promoter and 3′UTR polymorphisms with sporadic forms, point to a gene-dosage effect for SNCA in PD pathogenesis [9]. Studies in individuals with alcoholism [74] and in anorexia patients [75] revealed hypermethylation of the SNCA promoter, suggesting that the gene could be epigenetically regulated. The analysis of SNCA alleles in a PD patient heterozygous for the A53T mutation, the first mutation to be implicated in PD pathogenesis, revealed that SNCA showed monoallelic expression in this patient, with epigenetic silencing of the mutated allele due to histone modifications but not DNA methylation, and upregulation of the wild-type allele resulting in higher mRNA levels than in matched control subjects [76]. Others observed that the methylation of human SNCA intron 1 decreases gene expression, while inhibition of DNA methylation activates SNCA expression. They also observed that DNA methylation of SNCA intron 1 was reduced in several brain regions of sporadic PD patients, including the substantia nigra, putamen, and cortex, pointing toward an epigenetic regulation of SNCA expression in PD [72]. Another research group identified an SNCA CpG island in which the methylation status altered along with increased SNCA expression. Postmortem brain analysis revealed regional nonspecific methylation differences in this CpG region in the anterior cingulate and putamen among controls and PD subjects; however, in the substantia nigra of PD individuals, the methylation of this region was significantly decreased [73]. Both findings are consistent with previous reports indicating increased SNCA mRNA levels in PD substantia nigra tissue [77, 78]. A recent paper suggested that α-synuclein sequesters DNA methyltransferase 1 (DNMT1) from the nucleus [79]. DNMT1 is the maintenance DNA methylation enzyme which is abundantly expressed in the adult brain and is mainly located in the nuclear compartment. The researchers observed a reduction of nuclear DNMT1 levels in human postmortem brain samples from PD and from patients with dementia with Lewy bodies (DLBs) as well as in the brains of α-synuclein transgenic mice models. Furthermore, sequestration of DNMT1 in the cytoplasm resulted in global DNA hypomethylation in human and mouse brains, involving CpG islands upstream of SNCA and other genes. The nuclear DNMT1 levels were partially rescued by overexpression of DNMT1 in neuronal cell cultures and in α-synuclein transgenic mice brains. Therefore, the authors suggested that the association of DNMT1 and α-synuclein might mediate aberrant subcellular localization of DNMT1, resulting in epigenetic modifications in the brain [79].

4.1.2. Other Genes. In addition to its association with ARJP, loss of heterozygosity of parkin has been found in several types of malignant tumors, including ovarian, breast, and hepatocellular tumors, and abnormal methylation of parkin promoter was observed in patients with cancer [80]. The levels of methylation of the parkin gene promoter were revealed in samples from PD patients with heterozygous parkin mutations, PD patients without parkin mutations, and normal controls. No difference was observed between the three
groups, suggesting that parkin promoter methylation is unlikely to play a role in the pathogenesis and development of PD [101]. The UCHL-1 gene promoter was found to be hypermethylated in various types of cancer [102, 103]. However, the analysis of UCHL-1 promoter methylation in the frontal cortex of PD patients and controls revealed no significant differences between the groups [104]. In the same study the authors evaluated the methylation profiles of MAPT promoter in the frontal cortex and hippocampus of controls, Alzheimer’s disease patients, PD patients, and subjects with other tauopathies and synucleinopathies. No differences in the percentage of CpG methylation were found between control and disease samples or among the different pathological entities in any region analyzed [104]. Another study reported methylation differences in the gene coding for tumor necrosis alpha (TNFA) between the cortex and the substantia nigra, but these differences were present in PD cases and controls [105]. The analysis of the original Chilean family with Kufor-Rakeb syndrome that led to the discovery of the ATP13A2 gene at the PARK9 locus also revealed that there was no significant correlation between DNA methylation of the ATP13A2 promoter region and disease progression [106]. However, the recent collaborative study of the IPDGC and WTCCC2 on a dataset of post-mortem brain samples assayed for gene expression (n = 399) and methylation (n = 292), revealed methylation and expression changes associated with PD risk variants in PARK16/1q32, GPNMB, and STX1B, suggesting that the SNCA gene is unlikely to be the only one subjected to epigenetic regulation in PD brains [68]. In addition, an aging-associated alteration of subtelomeric methylation patterns was observed in peripheral leukocytes of Japanese PD patients that showed fewer short telomeres than healthy controls. Moreover, short telomeres in PD patients showed a constant methylation pattern, whilst an age-related demethylation of short telomeres was observed in controls [100].

### 4.2. Histone Modifications

Gene expression profiles are modulated not only by promoter methylation but also by the chromatin state. Indeed, chromatin can exist in a condensate inactive state (heterochromatin) or in a noncondensate and transcriptionally active state (euchromatin). Conformational changes in histone proteins or modifications of the way in which DNA wraps around the histone octamer in nucleosomes may either alter or facilitate the access of the transcriptional machinery to the promoter region of some genes, leading to gene silencing or activation, respectively. Histone tail modifications include acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, and other post-translational modifications. Histone tail acetylation is associated with chromatin relaxation and transcriptional activation, while deacetylation is related to a more condensed chromatin state and transcriptional repression [107]. Histone acetyltransferases (HATs) catalyze the acetylation of lysine residues in histone tails, whereas histone deacetylation is mediated by histone deacetylases (HDACs). Another frequently studied modification of histone tails is methylation on either lysine or arginine residues mediated by histone methyltransferases. Methylation of histone tails can be associated with either condensation or relaxation of the chromatin structure, since several sites for methylation are

### Table 4: Epigenetic changes of PD related genes or PD tissues.

| Gene                  | Observation                                                                 | Refs |
|-----------------------|-----------------------------------------------------------------------------|------|
| Reduced SNCA methylation in the substantia nigra of PD patients | [72, 73] |
| α-synuclein sequesters DNMT1 from the nucleus resulting in aberrant DNA methylation | [79] |
| SNCA gene silencing mediated by histone modifications | [76] |
| α-synuclein binds to histones and inhibits histone acetylation | [81–83] |
| Histone deacetylase inhibitors are neuroprotective against α-synuclein mediated neurotoxicity in PD animal models | [82, 84–90] |
| α-synuclein expression in C. elegans results in down-regulation of genes coding for histones | [91] |
| miR-10a, -10b, -212, -132, -495 were impaired in presymptomatic α-synuclein transgenic mice | [92] |
| miR-7 and mir-153 regulates α-synuclein levels | [93, 94] |
| miR-64 and mir-65 and let-7 were co-under-expressed in α-synuclein transgenic C. elegans | [95] |
| LRRK2 Mutant LRRK2 antagonizes miR-184* and let7 in Drosophila PD models | [96] |
| parkin let-7 family miRNAs let-7 were co-under-expressed in parkin transgenic C. elegans | [95] |
| PARK16/1q32, GPNMB, STX1B Aberrant gene methylation observed in post-mortem PD brains | [68] |
| Observation | Refs |
| PD brains miR-133b was deficient in midbrain from PD patients | [97] |
| PD brains miR-34b/c down-regulation was observed in pre-motor stages of PD and resulted in altered expression of DJ1 and parkin proteins | [98] |
| PD lymphocytes Altered expression of miR-1, miR-16-2*, miR-22*, miR26a2*, miR29, miR30 | [99] |
| PD leukocytes Altered methylation patterns of subtelomeric regions | [100] |
present on each tail thus allowing several combinations [107, 108]. Little is still known concerning histone modifications in PD brains and most of the current knowledge is derived from studies in cell cultures and animal models of the disease, such as those induced by mitochondrial toxins, including 1-methyl-4-phenylpyridinium (MPP+), paraquat, and rotenone, or those overexpressing human α-synuclein (Table 4). However, those studies have revealed that α-synuclein interacts with histones and inhibits histone acetylation [81, 82] and that several histone deacetylase inhibitors (HDACIs) are neuroprotective against α-synuclein-mediated toxicity [82, 84–87]. Particularly, studies performed in nigral neurons of mice exposed to the herbicide paraquat revealed that α-synuclein translates into the nucleus and binds with histones [81]. Studies in Drosophila showed that α-synuclein mediates neurotoxicity in the nucleus, binds directly to histone H3, and inhibits histone acetylation. The toxicity of α-synuclein was rescued by the administration of HDACIs [82]. The inhibition of the histone deacetylase Sirtuin 2 rescued α-synuclein-mediated toxicity in several models of PD [84]. In addition valproic acid (VPA) resulted in inhibition of histone deacetylase activity and in an increase of histone H3 acetylation in brain tissues of rats and resulted neuroprotective in a rat model of PD (obtained with the administration of the mitochondrial toxin rotenone), counteracting α-synuclein translocation into the nuclei [85]. Studies in rat and human neuronal cell cultures also revealed that HDACIs prevent MPP+ -mediated cytotoxicity [86]. Neurotoxic pesticides and paraquat were shown to increase histone acetylation in mice brains or cell culture models [87, 88], and additional studies reported protective effects of HDACIs on dopaminergic neurons following a neurotoxic-induced insult [89, 90]. A recent study in α-synuclein transgenic mice revealed that α-synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity [83]. A genome-wide expression screen was performed in C. elegans overexpressing human α-synuclein, and nine genes that form histones H1, H2B, and H4 were downregulated [91]. Overall, these studies point to a role for histone modifications in α-synuclein-mediated as well as environmental-induced dopaminergic neuronal cell death. Moreover, the accumulation of misfolded proteins in proteinaceous inclusions termed aggresomes is a cytoprotective response serving to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy. Histone deacetylase 6 (HDAC6) plays a fundamental role in aggresome formation. HDAC6 is concentrated in Lewy bodies in PD and dementia with LBs, and the Drosophila histone deacetylase 6 (dHDAC6) was shown to play a critical role in the protection of dopaminergic neurons and promoted the formation of α-synuclein inclusions in a Drosophila PD model expressing human α-synuclein. On the contrary, mutation of dHDAC6 resulted in the accumulation of toxic α-synuclein oligomers [109]. It was suggested that the accumulation of HDAC6 might be specific to α-synucleinopathy and that LBs might represent cytoprotective responses to sequester toxic proteins [110]. Aggresome formation involves several regulators, including HDAC6, parkin, ataxin-3, and ubiquilin-1 [111].

It has been recently shown in neuronal cell cultures that HDAC6 participates in the degradation of MPP+ induced aggregates of α-synuclein by regulating the aggresome-autophagy pathway [112].

4.3. RNA-Mediated Epigenetic Mechanisms. MicroRNAs (miRNAs) are a group of small noncoding RNAs that bind to the 3′ untranslated region (3′ UTR) of target mRNAs and mediate their posttranscriptional regulation leading to either degradation or translational inhibition, depending on the degree of sequence complementarity. In 2007 Kim et al. investigated the role of miRNAs in mammalian midbrain dopaminergic neurons and identified an miRNA, miR-133b, that is specifically expressed in midbrain dopaminergic neurons and is deficient in midbrain tissue from patients with PD. miR-133b regulates the maturation and function of midbrain dopaminergic neurons within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3 [97]. Subsequently, others observed that the FGF20 rs12720208 polymorphism disrupts a binding site for miR-433, increasing translation of FGF20 in vitro and in vivo, and suggested that this could represent a risk factor for PD [113]. However, a recent study failed to confirm the association between rs12720208 and PD risk, or any effect of miR-433 variants to PD pathogenesis [114]. MicroRNA expression analysis in brains of early symptomatic α-synuclein(A30P)-transgenic mice showed that the levels of several miRNAs (miR-10a, -10b, -212, -132, -495) were significantly altered. MiR-132 was reported to be highly inducible by growth factors and to be a key regulator of neurite outgrowth [92]. Others observed that miR-7, which is expressed mainly in neurons, represses α-synuclein protein levels binding to α-synuclein mRNA. Further, miR-7 expression decreased in MPP+-induced models of PD in cultured cells and in mice, thereby contributing to increased α-synuclein expression [93]. Another study confirmed that mir-7 regulates α-synuclein levels together with mir-153. Both miRNAs bind specifically to the 3′-untranslated region of α-synuclein and downregulate its mRNA and protein levels, with their effect being additive. They are expressed predominantly in the brain with a pattern that mirrors synuclein expression in different tissues as well as during neuronal development, likely playing a tuning role in the amount of α-synuclein produced [94]. The analysis of C. elegans models of PD revealed that several miRNAs were underexpressed in those animals; particularly the family of miR-64 and miR-65 were co-underexpressed in α-synuclein transgenic animals, and members of let-7 family co-underexpressed in both α-synuclein and parkin strains [95]. A recent study demonstrates that blood samples can be used as a source of miRNAs associated to PD. Six differentially expressed miRNAs were identified. While miR-1, miR-22*, and miR-29 expression levels allowed to distinguish nontreated PD patients from healthy subjects, miR-16-2*, miR-26a*, and miR30a differentially treated from untreated PD patients [99]. A recent miRNA profiling of PD brains identified early downregulation of miR-34b/c which modulate mitochondrial function. Particularly, misregulation of miR-34b/c was detected in premotor...
stages (stages 1–3) of the disease, and thus in cases that did not receive any PD-related treatment during life, and miR-34b/c downregulation was coupled to a decrease in the expression of DJ1 and Parkin proteins [98]. Moreover, studies in Drosophila bearing LRRK2 PD-associated mutations revealed that pathogenic LRRK2 antagonizes let-7 and miR-184*, leading to the overproduction of the E2F1/DP complex involved in cell cycle and survival control [96]. Overall, these studies indicate microRNA-mediated mechanisms in PD pathogenesis (Table 4).

5. Conclusions

Several advances have been gained in our understanding of the genetics of PD since the first report [5] of a SNCA gene mutation causing familial autosomal dominant PD in 1997 (Table 1). Studies on familial recessive forms of the disease have highlighted a central role for mitochondrial damage, repair, and turnover in the pathophysiology of the disease, with parkin, DJ1, PINK1, and FBX07, participating in the same or in similar/overlapping mitochondrial pathways. In addition, as suggested by Hardy [24], both glucocerebrosidase and ATP13A2 are lysosomal enzymes, indicating a second PD pathway involving lysosomes. In contrast, α-synuclein and LRRK2 biology is still poorly understood, despite that both proteins are central to the disease etiology [24]. Association studies in sporadic cases and the recent application of genome-wide technology led to the identification of almost 20 genes that could modify the individual risk for the idiopathic forms of the disease (Table 3), and additional genes are expected to be unravelled within the next future. Public databases, such as the PD mutation database (http://www.molgen.ua.ac.be/PDmutDB/) and the PDGene database [52], have been created to continuously update the genetics of either familial or idiopathic forms, respectively. There is however a growing evidence that, in addition to genetics of either familial or idiopathic forms, respectively. Base [52], have been created to continuously update the www.molgen.ua.ac.be/PDmutDB/) and the PDGene database.

References

[1] B. Thomas and M. F. Beal, “Molecular insights into Parkinson’s disease,” F1000 Medicine Reports, vol. 3, no. 7, 2011.
[2] K. Nuytemans, J. Theuns, M. Cruts, and C. Van Broeckhoven, “Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update,” Human Mutation, vol. 31, no. 7, pp. 763–780, 2010.
[3] A. Ramirez, A. Heimbach, J. Gründemann et al., “Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase,” Nature Genetics, vol. 38, no. 10, pp. 1184–1191, 2006.
[4] L. Migliore and F. Coppé, “Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases,” Mutation Research, vol. 667, no. 1-2, pp. 82–97, 2009.
[5] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson’s disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.
[6] R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998.
[7] J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004.
[8] A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson’s disease,” Science, vol. 302, no. 5646, p. 841, 2003.
[9] M. C. Chartier-Harlin, J. Kachergus, C. Roumier et al., “α-synuclein locus duplication as a cause of familial Parkinson’s disease,” The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004.
[10] C. Paisán-Ruiz, S. Jain, E. W. Evans et al., “Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease,” Neuron, vol. 44, no. 4, pp. 595–600, 2004.
[11] A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004.
[12] T. Kitada, S. Asakawa, N. Hattori et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,” Nature, vol. 392, no. 6673, pp. 605–608, 1998.
[13] E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1,” Science, vol. 304, no. 5674, pp. 1158–1160, 2004.
[14] C. M. Van Duijn, M. C. J. Dekker, V. Bonifati et al., “PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36,” American Journal of Human Genetics, vol. 69, no. 3, pp. 629–634, 2001.
[15] P. J. Lockhart, S. Lincoln, M. Bullihan et al., “DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function,” Journal of Medical Genetics, vol. 41, no. 3, p. e22, 2004.
[16] D. J. Hampshire, E. Roberts, Y. Crow et al., “Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36,” Journal of Medical Genetics, vol. 38, no. 10, pp. 680–682, 2001.
[17] Y. Liu, L. Fallon, H. A. Lashuel, Z. Liu, and P. T. Lansbury, "The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson’s disease susceptibility," _Cell_, vol. 111, no. 2, pp. 209–218, 2002.

[18] C. Lautier, S. Goldwurm, A. Durr et al., "Mutations in the GIGYF2 (TNRCS1) gene at the PARK11 locus in familial Parkinson disease," _American Journal of Human Genetics_, vol. 82, no. 4, pp. 822–833, 2008.

[19] S. Higashi, E. Iseki, M. Minegishi, T. Togo, T. Kabuta, and K. Wada, "GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF-1-induced ERK1/2 activation," _Journal of Neurochemistry_, vol. 115, no. 2, pp. 423–437, 2010.

[20] K. M. Strauss, L. M. Martins, H. Plun-Favreau et al., "Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease," _Human Molecular Genetics_, vol. 14, no. 15, pp. 2699–2711, 2005.

[21] C. Paisán-Ruiz, R. Guevara, M. Federo et al., "Early-onset L-dopa-responsive Parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and Spatac6 mutations," _Movement Disorders_, vol. 25, no. 12, pp. 1791–1800, 2010.

[22] S. Shojaeef, F. Sina, S. S. Banhosseini et al., "Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays," _American Journal of Human Genetics_, vol. 82, no. 6, pp. 1375–1384, 2008.

[23] A. D. Fonzio, M. C. I. Dekker, P. Montagna et al., "FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome," _Neurology_, vol. 72, no. 3, pp. 240–245, 2009.

[24] J. Hardy, "Genetic analysis of pathways to parkinson disease," _Neuron_, vol. 68, no. 2, pp. 201–206, 2010.

[25] M. A. Nalls, V. Plagnol, D. G. Hernandez et al., "Imputation of sequence variants for identification of genetic risks for Parkinson disease: focus on epigenetics," _Nature Genetics_, vol. 47, no. 5, pp. 573–580, 2011.

[26] F. Coppedè, "One-carbon metabolism and Alzheimer’s disease: focus on epigenetics," _Current Genomics_, vol. 11, no. 4, pp. 246–260, 2010.

[27] I. A. Qureshi and M. F. Mehler, "Advances in epigenetics and epigenomics for neurodegenerative diseases," _Current Neurology and Neuroscience Reports_, vol. 11, no. 5, pp. 464–473, 2011.

[28] S. C. F. Marques, C. R. Oliveira, C. M. F. Pereira, and T. F. Outeiro, "Epigenetics in neurodegeneration: a new layer of complexity," _Progress in Neuro-Psychopharmacology and Biological Psychiatry_, vol. 35, pp. 348–355, 2011.

[29] M. Chen and L. Zhang, "α-Synuclein aggregation is regulated by mitochondrial morphology," _Drug Discovery Today_, vol. 16, no. 23–24, pp. 1007–1018, 2011.

[30] C. Dumanchin, A. Camuzat, D. Campion et al., "Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism," _Human Molecular Genetics_, vol. 7, no. 11, pp. 1825–1829, 1998.

[31] M. G. Spillantini and M. Goedert, "Tau mutations in familial frontotemporal dementia," _Brain_, vol. 123, no. 5, pp. 857–859, 2000.

[32] I. Lastres-Becker, U. Rüb, and G. Auburger, "Spinocerebellar ataxia type 2 (SCA2)," _Cerebellum_, vol. 7, no. 2, pp. 115–124, 2008.

[33] C. A. Matos, S. de Macedo-Ribeiro, and A. L. Carvalho, "Polyglutaminases: the special case of ataxin-3 and Machado-Joseph disease," _Progress in Neurobiology_, vol. 95, no. 1, pp. 26–48, 2011.

[34] C. S. Lu, H. C. Chang, P. C. Kuo et al., "The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family," _Parkinsonism and Related Disorders_, vol. 10, no. 6, pp. 369–373, 2004.

[35] J. M. Kim, S. Hong, P. K. Gyongy et al., "Importance of low-range CAG expansion and CAA interruption in SCA2 parkinsonism," _Archives of Neurology_, vol. 64, no. 10, pp. 1510–1518, 2007.

[36] M. Anheim, C. Lagier-Tourenne, G. Stevanin et al., "SPG11 spastic paraplegia: a new cause of juvenile parkinsonism," _Journal of Neurology_, vol. 256, no. 1, pp. 104–108, 2009.

[37] A. Guidubaldi, C. Piano, F. M. Santorelli et al., "Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive parkinsonism," _Movement Disorders_, vol. 26, no. 3, pp. 553–556, 2011.

[38] D. Orsucci, E. Caldara, L. M. Mancuso, and G. Siciliano, "POLG1-Related and other Mitochondrial Parkinsonisms: an overview," _Journal of Molecular Neuroscience_, vol. 44, pp. 17–24, 2011.

[39] A. Abeliovich, Y. Schmitz, I. Fariñas et al., "Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system," _Neuron_, vol. 25, no. 1, pp. 239–252, 2000.

[40] S. Liu, I. Ninan, I. Antonova et al., "α-synuclein produces a long-lasting increase in neurotransmitter release," _EMBO Journal_, vol. 23, no. 22, pp. 4506–4516, 2004.

[41] I. F. Mata, P. J. Lockhart, and M. J. Farrer, "Parkin genetics: one model for Parkinson’s disease," _Human Molecular Genetics_, vol. 13, no. 1, pp. R127–R133, 2004.

[42] E. Leroy, R. Boyer, G. Auburger et al., "The ubiquitin pathway in Parkinson’s disease," _Nature_, vol. 395, no. 6701, pp. 451–452, 1998.

[43] D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, "Parkin is recruited selectively to impaired mitochondria and promotes their autophagy," _Journal of Cell Biology_, vol. 183, no. 5, pp. 795–803, 2008.

[44] H. Deng, M. W. Dodson, H. Huang, and M. Guo, "The Parkinson’s disease genes pINK1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila," _Proceedings of the National Academy of Sciences of the United States of America_, vol. 105, no. 38, pp. 14503–14508, 2008.

[45] A. C. Poole, R. E. Thomas, L. A. Andrews, H. M. McBride, A. J. Whitworth, and L. J. Pallanck, "The PINK1/Parkin pathway regulates mitochondrial morphology," _Proceedings of the National Academy of Sciences of the United States of America_, vol. 105, no. 5, pp. 1638–1643, 2008.

[46] A. K. Berger, G. P. Cortese, K. D. Amodeo, A. Weihofen, A. Letai, and M. J. LaVoie, "Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release," _Human Molecular Genetics_, vol. 18, no. 22, pp. 4317–4328, 2009.

[47] O. Rothfuss, H. Fischer, T. Hasegawa et al., "Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair," _Human Molecular Genetics_, vol. 18, no. 20, pp. 3832–3850, 2009.

[48] S. Kawajiri, S. Saiki, S. Sato, and N. Hattori, "Genetic mutations and functions of PINK1," _Trends in Pharmacological Sciences_, vol. 32, no. 10, pp. 573–580, 2011.

[49] H. Xiong, D. Wang, L. Chen et al., "Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation," _Journal of Clinical Investigation_, vol. 119, no. 3, pp. 650–660, 2009.

[50] K. J. Thomas, M. K. McCoy, J. Blackinton et al., "DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy," _Human Molecular Genetics_, vol. 20, no. 1, pp. 40–50, 2011.
A. Velayati, W. H. Yu, and E. Sidransky, “The role of glucocerebrosidase mutations in Parkinson’s disease,” *Journal of Biological Chemistry*, vol. 286, no. 34, pp. 29654–29662, 2011.

C. P. Zabetian, C. M. Hutter, S. A. Factor et al., “Association study confirms genetic risk underlying Parkinson’s disease,” *Nature Genetics*, vol. 74, no. 2, pp. 97–109, 2010.

A. Goris, C. H. Williams-Gray, G. R. Clark et al., “Tau and α-synuclein in microdissected dopaminergic substantia nigra neurons in Kufor-Rakeb syndrome-associated ATPL3A2 protein,” *Journal of Biological Chemistry*, vol. 286, no. 34, pp. 29654–29662, 2011.

D. M. Maraganore, M. De Andrade, A. Elbaz et al., “Colocalization analysis of α-synuclein gene promoter variability and Parkinson disease,” *Journal of the American Medical Association*, vol. 296, no. 6, pp. 661–670, 2006.

N. Tayebi, J. Walker, B. Stubblefield et al., “Distinct epigenetic alterations in Lewy body diseases,” *Molecular Psychiatry*, vol. 62, no. 2, pp. 145–153, 2007.

I. Schmitt, O. Kaut, and U. Wüllner, “Methylation status and neurodegenerative markers in Parkinson disease,” *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 12, pp. 1614–1620, 2007.

A. Jowaed, I. Schmitt, O. Kaut, and U. Wüllner, “Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains,” *Journal of Neuroscience*, vol. 30, no. 18, pp. 6355–6359, 2010.

D. Bönsch, B. Lenz, J. Kornhuber, and S. Bleich, “DNA hypermethylation of the alpha-synuclein promoter in patients with alcoholism,” *NeuroReport*, vol. 16, no. 2, pp. 167–170, 2005.

F. Frieling, A. Gozner, K. D. Römer et al., “Global DNA hypomethylation and DNA hypermethylation of the alpha-synuclein promoter in females with anorexia nervosa,” *Molecular Psychiatry*, vol. 12, no. 3, pp. 229–230, 2007.

G. E. Voutsinas, E. F. Stavrou, G. Karousos et al., “Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease,” *Human Mutation*, vol. 31, no. 6, pp. 685–691, 2010.

O. Chiba-Falek, G. J. Lopez, and R. L. Nussbaum, “Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients,” *Movement Disorders*, vol. 21, no. 10, pp. 1703–1708, 2006.

J. Gründemann, F. Schlaudraff, O. Haeckel, and B. Liss, “Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease,” *Nucleic Acids Research*, vol. 36, no. 7, article e38, 2008.

P. Desplats, B. Spencer, E. Coffee et al., “α-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases,” *Journal of Biological Chemistry*, vol. 286, no. 11, pp. 9031–9037, 2011.

X. Agirre, J. Román-Gómez, I. Vázquez et al., “Abnormal methylation of the common PARK2 and PARK6 promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia,” *International Journal of Cancer*, vol. 118, no. 8, pp. 1945–1953, 2006.

I. Goers, A. B. Manning-Bog, A. L. McCormack et al., “Nuclear localization of α-synuclein and its interaction with histones,” *Biochemistry*, vol. 42, no. 28, pp. 8465–8471, 2003.
[113] G. Wang, J. M. van der Walt, G. Mayhew et al., “Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein,” *American Journal of Human Genetics*, vol. 82, no. 2, pp. 283–289, 2008.

[114] L. de Mena, L. F. Cardo, E. Coto et al., “FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson’s disease in Spanish patients,” *Neuroscience Letters*, vol. 479, no. 1, pp. 22–25, 2010.

[115] S. R. D’Mello, “Histone deacetylases as targets for the treatment of human neurodegenerative diseases,” *Drug News and Perspectives*, vol. 22, no. 9, pp. 513–524, 2009.

[116] M. M. Harraz, T. M. Dawson, and V. L. Dawson, “MicroRNAs in Parkinson’s disease,” *Journal of Chemical Neuroanatomy*, vol. 42, no. 2, pp. 127–130, 2011.